Hansa Biopharma AB (publ) (LON:0RC7)
London
· Delayed Price · Currency is GBP · Price in SEK 22.72
-0.92 (-3.89%)
At close: Feb 21, 2025
Hansa Biopharma AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 405.28 | 732.06 | 1,496 | 651.34 | 1,139 | Upgrade
|
| Short-Term Investments | - | - | - | 237.62 | 238.14 | Upgrade
|
| Cash & Short-Term Investments | 405.28 | 732.06 | 1,496 | 888.96 | 1,378 | Upgrade
|
| Cash Growth | -44.64% | -51.07% | 68.31% | -35.47% | 129.17% | Upgrade
|
| Accounts Receivable | 144.97 | 78.03 | 42.96 | 9.71 | 0.11 | Upgrade
|
| Other Receivables | 32.57 | 15.73 | 24.22 | 13.53 | 7.59 | Upgrade
|
| Receivables | 177.54 | 93.76 | 67.18 | 23.24 | 7.7 | Upgrade
|
| Inventory | 2.61 | 1.51 | 0.97 | 0.24 | 0.1 | Upgrade
|
| Prepaid Expenses | - | 3.06 | 3.52 | 3.34 | 1.66 | Upgrade
|
| Other Current Assets | - | 24.76 | 36.85 | 26.56 | 6.43 | Upgrade
|
| Total Current Assets | 585.43 | 855.15 | 1,605 | 942.34 | 1,393 | Upgrade
|
| Property, Plant & Equipment | 17.88 | 27.07 | 35.84 | 41.71 | 9.7 | Upgrade
|
| Other Intangible Assets | 197.33 | 23.17 | 26.01 | 28.76 | 31.41 | Upgrade
|
| Long-Term Deferred Charges | - | 112.65 | 20.85 | - | - | Upgrade
|
| Total Assets | 800.64 | 1,018 | 1,687 | 1,013 | 1,434 | Upgrade
|
| Accounts Payable | 55.49 | 86.97 | 62.48 | 53.36 | 26.67 | Upgrade
|
| Accrued Expenses | 108.47 | 116.54 | 100.32 | 78.22 | 52.36 | Upgrade
|
| Current Portion of Leases | 7.68 | 7.5 | 7.17 | 6.89 | 4.42 | Upgrade
|
| Current Income Taxes Payable | 2.71 | 1.6 | 0.6 | - | 0.13 | Upgrade
|
| Current Unearned Revenue | 16.33 | 41.47 | 40.43 | 24.96 | 17.41 | Upgrade
|
| Other Current Liabilities | 64.48 | 66.91 | 53.71 | 7.79 | 13.22 | Upgrade
|
| Total Current Liabilities | 255.17 | 320.99 | 264.71 | 171.22 | 114.2 | Upgrade
|
| Long-Term Debt | 1,065 | 844.9 | 762.6 | - | - | Upgrade
|
| Long-Term Leases | 6.68 | 14.36 | 21.33 | 28.49 | 0.63 | Upgrade
|
| Long-Term Unearned Revenue | - | - | 29.5 | 47.02 | 62.03 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 0.17 | 0.37 | 0.41 | 0.43 | 0.42 | Upgrade
|
| Other Long-Term Liabilities | 63.3 | 5.3 | 5.95 | 8.08 | 15.09 | Upgrade
|
| Total Liabilities | 1,390 | 1,186 | 1,084 | 255.24 | 192.37 | Upgrade
|
| Common Stock | -589.32 | 55.03 | 55.03 | 46.34 | 45.9 | Upgrade
|
| Additional Paid-In Capital | - | 3,083 | 3,022 | 2,573 | 2,509 | Upgrade
|
| Retained Earnings | - | -3,303 | -2,471 | -1,860 | -1,312 | Upgrade
|
| Treasury Stock | - | -2.36 | -2.59 | -1.86 | -1.42 | Upgrade
|
| Comprehensive Income & Other | - | -0.41 | 0.01 | 0.13 | -0.14 | Upgrade
|
| Shareholders' Equity | -589.32 | -167.88 | 602.91 | 757.57 | 1,242 | Upgrade
|
| Total Liabilities & Equity | 800.64 | 1,018 | 1,687 | 1,013 | 1,434 | Upgrade
|
| Total Debt | 1,079 | 866.77 | 791.09 | 35.38 | 5.05 | Upgrade
|
| Net Cash (Debt) | -673.73 | -134.71 | 705.09 | 853.58 | 1,372 | Upgrade
|
| Net Cash Growth | - | - | -17.40% | -37.81% | 131.98% | Upgrade
|
| Net Cash Per Share | -10.72 | -2.56 | 15.70 | 19.19 | 32.54 | Upgrade
|
| Filing Date Shares Outstanding | 67.81 | 52.67 | 52.44 | 44.47 | 44.47 | Upgrade
|
| Total Common Shares Outstanding | 67.81 | 52.67 | 52.44 | 44.47 | 44.47 | Upgrade
|
| Working Capital | 330.26 | 534.16 | 1,340 | 771.12 | 1,279 | Upgrade
|
| Book Value Per Share | -8.69 | -3.19 | 11.50 | 17.03 | 27.93 | Upgrade
|
| Tangible Book Value | -786.65 | -191.05 | 576.9 | 728.81 | 1,211 | Upgrade
|
| Tangible Book Value Per Share | -11.60 | -3.63 | 11.00 | 16.39 | 27.22 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.